2017 Speaking Faculty

• Hinrich Abken, Ph.D., Professor & Head, Research, Molecular Medicine, University of Cologne
• Amir R. Aref, Ph.D., Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
• Roy D. Baynes, M.D., Ph.D., Senior Vice President and Head, Global Clinical Development, CMO, Merck Sharp & Dohme
• Stephen Beers, Ph.D., Associate Professor, Cancer Sciences Unit, Faculty of Medicine, University of Southampton
• Chiara Bonini, Ph.D., Università Vita-Salute San Raffaele and Ospedale San Raffaele, Milan
• Kerry Chester, Ph.D., Professor, UCL Cancer Institute
• Shaun Cordoba, Ph.D., Research Scientist, Autolus
• Angus Dalgleish, M.D., Professor, Oncology, St. George’s University of London
• John Desjarlais, Ph.D., CSO, Xencor, Inc.
• Joseph Dukes, Ph.D., Head, Preclinical Biology, Cell Biology, Immunocore Ltd.
• Lindy Durrant, Ph.D., Professor, Cancer Immunotherapy, University of Nottingham; Joint CEO & CSO, Scancell
• Andrea van Elsas, Ph.D., CSO, Aduro Biotech Europe
• Zelig Eshhar, Ph.D., Chair, Cancer Immunotherapy, Research and Development, Sourasky Medical Center, Tel Aviv
• David Feltquate, M.D., Ph.D., Vice President, Oncology Development, Bristol-Myers Squibb
• Kandeepan Ganeshalingam, M.D., Executive Director, Oncology Therapeutic Area Head, European Clinical Development, Merck Sharp & Dohme
• Tariq Ghayur, Ph.D., Distinguished Research Fellow, DVD-Ig and Novel Biologics, Global Biologics, AbbVie, Inc.
• David Gilham, Ph.D., Vice President, Research & Development, Celyad S.A.
• Bruno Gomes, Ph.D., Director, Tumour Immunology, Iteos Therapeutics
• Lucie Heinzerling, M.D., Ph.D., MPH, Head of Dermatooncology, University Hospital of Erlangen
• Lana Kandalaft, Pharm.D., Ph.D., Assistant Professor & Director, Center for Experimental Therapeutics, Department of Oncology, University of Lausanne; Tenure Track Assistant Professor, Ludwig Cancer Research Lausanne Branch
• Bo Kara, Ph.D., Head, Process Development, Cell Gene Therapy CMC, GlaxoSmithKline
• Maria Karasarides, Ph.D., Senior Director, Immuno-Oncology, Global Medicines Development, AstraZeneca
• Ioannis Karydis, D.Phil., MRCP, Associate Professor, Oncology, Cancer Sciences Unit, University of Southampton
• Christian Klein, Ph.D., Distinguished Scientist, Head, Oncology Programs, Cancer Immunotherapy Discovery, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich
• John Maher, M.D., Ph.D., Consultant and Senior Lecturer, Immunology, Cancer Studies, King’s College London
• Ryan McCoy, Eng.D., MEng, Senior Process Development Scientist, Industrialisation Group, Cell and Gene Therapy, Catapult
• Alan Melcher, M.D., Ph.D., Professor, Translational Immunotherapy, The Institute of Cancer Research, London
• Paul Moore, Ph.D., Vice President, Cell Biology and Immunity, Macrogenics, Inc.
• Dario Neri, Ph.D., Professor, Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH), Zurich
• Christian Ottensmeier, M.D., Ph.D., Professor, Experimental Cancer Medicine, University of Southampton
• Mark Paris, Ph.D., Technical Liaison, Mitra Biotech
•  
• Madhusudan Peshwa, Ph.D., CSO, MaxCyte
• Christine Rothe, Ph.D., Vice President, Discovery & Alliance Management, Pieris Pharmaceuticals, Inc.
• Catherine Sabatos-Peyton, Ph.D., Senior Investigator II, Exploratory Immuno-Oncology, Novartis Institutes for BioMedical Research (NIBR)
• Maike Schmidt, Ph.D., Scientist and Group Leader, Cancer Immunology, Genentech, Inc.
• Katherine J. Seidl, Ph.D., Director, Immunotherapy, bluebird bio
• Armin Sepp, Ph.D., Senior Scientific Investigator, Systems Modeling and Translational Biology, GlaxoSmithKline
• Andrew Sewell, Ph.D., Professor, Institute of Infection & Immunity, Cardiff University School of Medicine
• Daniel E. Speiser, M.D., Professor, Clinical Tumor Biology & Immunotherapy, Department of Oncology, University of Lausanne
• Hans Stauss, M.D., Ph.D., Professor and Director, Immunity & Transplantation, University College London
• Catelijne Stortelers, Ph.D., Senior Project Leader, Technology, Discovery, Ablynx NV
• Stefan Symeonides, Ph.D., Senior Lecturer, Experimental Cancer Medicine, Edinburgh Cancer Research Centre, University of Edinburgh
• Sebastian Theurich, M.D., Lecturer, Internal Medicine, Hematology and Oncology, University Hospital Cologne, Germany
• Martin Treder, Ph.D., CSO, Affimed
• Bob Uger, Ph.D., CSO, Trillium Therapeutics, Inc.
• Frederick Arce Vargas, Ph.D., Haematology, University College London Cancer Institute
• Nicolai Wagtmann, Ph.D., Executive Vice President and CSO, Innate Pharma
• Jon Wigginton, M.D., Senior Vice President, Clinical Development & CMO, MacroGenics
• Robert W. Wilkinson, Ph.D., Director, Oncology Research, MedImmune Ltd.